Global Anti-diabetic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Diabetes Type (Type 1, Type 2), By Drug Type (Amylinomimetic Drug, Biguanides, Alpha-glucosidase Inhibitors, Sodium-glucose Transporter (SGLT) 2 Inhibitors, Others), By Route Of Administration (Oral, Insulin), By Sales Channel (Presciption, Over-The-Counter (OTC)), And By Geography - Forecasts From 2022 To 2027

Published:  Jul 2022 Report Code: KSI061613514 Pages: 120

The global anti-diabetic drug market is estimated to grow at a CAGR of 13.18% to reach a market value of US$183.582 billion by 2027 from US$77.162 billion in 2020. 

Diabetes Prevalence to drive the market

The rising prevalence of diabetes worldwide is the primary driver of the global anti-diabetic drug market. According to the International Diabetes Foundation, in 2019, approximately 463 million adults (20-79 years) had diabetes which is projected to rise to700 million by 2045. The significant market growth is attributed to the increasing number of patients suffering from Type 2 diabetes in different regions. According to the International Diabetes Foundation, the number of people with Type 2 diabetes is increasing in many countries.

Unhealthy dietary habits to augment the profitability

Unhealthy dietary habits among people of all ages have led to a drastic rise in diabetic patients globally. Furthermore, the rising cost of treating diabetes is also spurring the demand for anti-diabetic drugs, thereby bolstering the global anti-diabetic drug market growth.

According to the International Diabetes Foundation, in 2019, diabetes led to more than US$750 billion in health expenditure which is 10 percent of total spending on adults. Global pharmaceutical companies are funnelling investments in research and development to develop advanced anti-diabetic drugs as per the growing requirement. The growing geriatric population is another factor that is driving the market growth of anti-diabetic drugs. According to the International Diabetes Foundation, 1 in 5 older adults aged 65 years and above have diabetes. Rising government expenditure and health awareness campaigns to treat diabetes effectively boost global anti-diabetic drug market growth.

The global anti-diabetic drug market is segmented by diabetes type, drug type, route of administration, sales channel, and geography. Based on diabetes type, the global anti-diabetic drug market is segmented into Type 1 and Type 2. The global anti-diabetic drug market segmentation based on the drug type is done by Amylinomimetic drug, Biguanide, Alpha-glucosidase inhibitors, Sodium-glucose transporter (SGLT) 2 inhibitors, and others. By route of administration, the market segmentation is done as oral and insulin. By the sales channel, the global anti-diabetic drug market is segmented as prescription and over-the-counter (OTC).   

The sale of OTC anti-diabetic drugs is on the rise

The prescribed anti-diabetic drug market holds a noteworthy market share throughout the forecast period. This is because these drugs are prescribed to patients by doctors with other diabetes-related therapies. Moreover, the wrong dosage of some drugs can lead to a harmful impact on the patient’s health.

However, many pharmaceutical companies are launching OTC anti-diabetic drugs, especially in emerging economies, as these are cheaper than the prescribed drugs. Thus, the OTC ant-diabetic drug market will experience a significant CAGR between 2019 and 2025, owing to rising sales in developing economies.

By geography, North America holds a significant market share

Regionally, the global anti-diabetic drug market is classified into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America accounted for a significant share of the global anti-diabetic drug market in 2019.

The presence of major pharmaceutical companies in the region contributes significantly to the notable market share of this region in the global anti-diabetic drug market. The increasing number of diabetic patients in countries like the U.S. and Canada is augmenting the demand for anti-diabetic drugs.

According to the Centers for Disease Control and Prevention (CDC), more than 100 million American adults suffer from diabetes or prediabetes. As per the statistics provided by the Canada Diabetes Association, around 90 percent of diabetic Canadians have Type 2 diabetes. Furthermore, there has been a rise in the prevalence of diabetes among children due to an unhealthy lifestyle. In the U.S., for example, the rate of newly diagnosed cases of Type 1 diabetes among kids aged 0-19 rose by 4.2 percent annually.

APAC to witness substantial growth

However, the APAC region is projected to witness substantial market growth during the forecast period owing to the continuous rise in diabetic patients in countries like China, India, and South Korea. The easy availability of cheaper OTC (over-the-counter) anti-diabetic drugs in Asia Pacific countries is also contributing to the market growth of the region’s anti-diabetic drug market during the forecast period.

Key Developments

  • May 2022: the U.S. Food and Drug Administration has authorized Mounjaro (tirzepatide) injectable drug to help individuals with type 2 diabetes better regulate their blood sugar levels. In clinical investigations, Mounjaro was compared to other diabetic treatments and shown to be more effective at lowering blood sugar.
  • April 2022: A revolutionary fixed-dose combination (FDC) of Teneligliptin, a popular DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), and Pioglitazone has been introduced by Glenmark Pharmaceuticals Limited (Glenmark) in India. This FDC, marketed by Glenmark under the name Zita Plus Pio, includes the active ingredients teneligliptin (20 mg) and pioglitazone (15 mg) and is intended to be taken once a day by people suffering from type-2 diabetes.
  • March 2020:  The Indian company Natco Pharma has recently launched the generic versions of AstraZeneca’s patented anti-diabetes brand, Farxig. The company is selling the generic drug under the brand Dapnat and will be available in5mg and 10mg tablets.
  • January 2020:  The U.S. Food and Drug Administration (FDA) approved the first oral therapy to combine three medications into one pill for Type 2 diabetes from Eli Lilly and Co. and Boehringer Ingelheim. The combined medication includes the DPP IV inhibitor linagliptin, SGLT2 inhibitor empagliflozin, and metformin hydrochloride extended-release.
  • December 2019: - Cadila Healthcare launched Vinglyn and Vinglyn M, an affordable oral anti-diabetic drug in India. The drug belongs to the class of DPP4 inhibitors and is one of the recent advancements in diabetes care and management.
  • April 2019: - Glenmark Pharmaceuticals announced to launch of Remogliflozin etabonate in India. This drug is used to treat adult patients with Type 2 diabetes. 

Impact of the COVID-19 pandemic

The COVID-19 pandemic led to a significant decline in the global economy and revenue. Owing to the suspension of major industrial activities, other sectors suffered. The anti-diabetic drug market faced a minimal initial decline in sales, owing to the disruption in supply and distribution lines. The extensive care required in the transportation of anti-diabetes drugs led to a decline in supply. However, with the increasing cases of diabetes among people, the market reported an increase in demand. Moreover, people with conditions like asthma and diabetes were more vulnerable to COVID-19 infection. This also led to an increase in demand for the diabetes drug market. Furthermore, according to the American Heart Association, approximately 1.64 million deaths worldwide were linked to diabetes in the year 2020. Owing to the rapidly increasing cases of diabetes worldwide, the anti-diabetic drug market is anticipated to increase substantially.

Segmentation

  • By Diabetes Type
    • Type 1
    • Type 2
  • By Drug Type
    • Amylinomimetic drug
    • Biguanides
    • Alpha-glucosidase inhibitors
    • Sodium-glucose transporter (SGLT) 2 inhibitors
    • Others
  • By Route of Administration
    • Oral
    • Insulin
  • By Sales Channel
    • Prescription
    • Over-The-Counter (OTC)
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Italy
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • UAE
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the anti-diabetic drug market size by 2027?
A1. The global anti-diabetic drug market is estimated to reach a market size of US$183.582 billion by 2027. 


Q2. What are the growth prospects for the anti-diabetic drug market?
A2. The anti-diabetic drug market is estimated to grow at a CAGR of 13.18% during the forecast period. 


Q3. What is the size of the global anti-diabetic drug market?
A3. Anti-diabetic Drug Market was valued at US$77.162 billion in 2020. 


Q4. What factors are anticipated to drive the anti-diabetic drug market growth?
A4. The rising prevalence of diabetes worldwide is the primary driver of the global anti-diabetic drug market. 


Q5. Which region holds the largest market share in the anti-diabetic drug market?
A5. North America accounted for a significant share of the global anti-diabetic drug market.

1. Introduction
1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Global Anti-Diabetic Drug Market Analysis, By Diabetes Type
5.1. Introduction
5.2. Type I
5.3. Type II

6. Global Anti-Diabetic Drug Market Analysis, By Drug Type
6.1. Introduction
6.2. Amylinomimetic drug
6.3. Biguanides
6.4. Alpha-glucosidase inhibitors
6.5. Sodium-glucose transporter (SGLT) 2 inhibitors
6.6. Others

7. Global Anti-Diabetic Drug Market Analysis, By Route of Administration
7.1. Introduction
7.2. Oral
7.3. Insulin

8. Global Anti-Diabetic Drug Market Analysis, By Sales Channel
8.1. Introduction
8.2. Prescription
8.3. Over-The-Counter (OTC)

9. Global Anti-Diabetic Drug Market Analysis, By Geography
9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. United Kingdom
9.4.4. Spain
9.4.5. Italy
9.4.6. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. Israel
9.5.3. UAE
9.5.4. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. India
9.6.4. South Korea
9.6.5. Taiwan
9.6.6. Thailand
9.6.7. Indonesia
9.6.8. Others

10. Competitive Environment and Analysis
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix

11. Company Profiles 
11.1. AstraZeneca
11.2. Pfizer Inc.
11.3. Merck & Co., Inc.
11.4. Novo Nordisk A/S
11.5. Eli Lilly and Company
11.6. Glenmark Pharmaceuticals Ltd.
11.7. Abbott
11.8. Boehringer Ingelheim International GmbH

AstraZeneca

Pfizer Inc.

Merck & Co., Inc.

Novo Nordisk A/S

Eli Lilly and Company

Glenmark Pharmaceuticals Ltd.

Abbott

Boehringer Ingelheim International GmbH

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us